|
Genetics of Hepatitis C Virus Infection Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Genetics of Hepatitis C Virus Infection conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Genetics of Hepatitis C Virus Infection Clinical research trials and Genetics of Hepatitis C Virus Infection health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Genetics of Hepatitis C Virus Infection. Genetics of Hepatitis C Virus Infection Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Genetics of Hepatitis C Virus Infection clinical trial. Human subjects often get the best healthcare possible for their Genetics of Hepatitis C Virus Infection condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetics of Hepatitis C Virus Infection  Genetics of Hepatitis C Virus Infection
Genetics of Hepatitis C Virus Infection
For Condition: Hepatitis C,Liver Disease
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: The course of hepatitis C varies among people infected with the virus. Some people respond to treatment while many do not; some recover completely while others remain chronically infected; and among those who remain infected, some have mild symptoms while others' symptoms are severe. This study will look for genetic factors that may contribute to these differences. Children over 2 years of age and adults with hepatitis C virus infection or with other kinds of liver disease (such as hepatitis B virus infection, primary biliary cirrhosis, Wilson's disease and others), and normal volunteers may be eligible for this study. Participants will provide 40 to 60 centiliters (1 to 2 ounces) of blood. DNA will be isolated from the white blood cells for analysis of genes involved in certain immune functions. The genetic findings from patients with hepatitis C, patients with other forms of liver disease, and normal volunteers will be compared to try to learn how the differences may influence the symptoms and course of hepatitis C and to understand how the virus causes disease. The results of this study may provide information useful for developing a vaccine and better treatments for hepatitis C.
Details: The diverse clinical syndromes associated with hepatitis C underscore the multifactorial and polygenic nature of HCV infection. Both viral and host factors likely contribute to variations in infection outcome, disease susceptibility and progression, and treatment response. This protocol will focus on the immunogenetics of HCV infection. Various candidate genes, most of them related to host immune response in microbial infection, have defined genetic polymorphisms that have been associated with variable manifestations of infections including malaria, tuberculosis, leprosy, AIDS and hepatitis B. In this proposal, we plan to collect peripheral blood mononuclear cells as a source of DNA from approximately 1500 patients with HCV infection, analyze genetic polymorphisms of various candidate genes in association with viral clearance, disease progression or treatment response, and characterize the functional consequences of these polymorphisms in patients with well-defined clinical sequelae of HCV infection. We will also collect blood from patients with other forms of liver diseases (approximately 300) or normal volunteers (approximately 200) as controls. By identifying relevant host factors genetically and investigating their molecular interactions with HCV, we may gain additional insights into HCV pathogenesis and uncover new potential targets for vaccine development and treatment intervention.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients who have recovered from past HCV exposure (positive anti-HCV but negative HCV viremia and absent liver disease). Patients with asymptomatic HCV infection (positive anti-HCV and HCV viremia, but persistently normal or minimally elevated ALT and normal or mild disease on liver biopsy). Patients with active liver disease (positive anti-HCV and HCV viremia, persistently elevated ALT and/or moderate disease on liver biopsy). Patients with active extrahepatic manifestations of HCV infection (cryoglobulinemia, glomerulonephritis, vasculitis, etc.). Patients with rapidly progressive, severe liver disease and/or hepatocellular carcinoma. Patients who have undergone or are undergoing treatment. Patients from a single-source outbreak of HCV infections (in which the viral factors should be identical and the patients are often from a homogeneous population with less genetic variability). HCV infected family members and twins. Patients with other forms of liver disease including HBV infection, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, hemochromatosis, and Wilson's Disease, as well as normal volunteers. EXCLUSION CRITERIA: Adult subjects with a Hct of less than 30 or pediatric subjects less than 25 will be excluded. Children with HCV infection younger than 2 years of age will be excluded. Unaffected healthy volunteers who are minors are not eligible for this study.
Total Enrollment: 9999999
Location and Contact Information:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 000125; 00-DK-0125
Study Start Date: May 4, 2000
Record last reviewed: April 19, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005657
Other Hepatitis C Studies:
1. Magnetic Resonance Imaging of Blood Flow in the Liver and Abdomen
2. Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction
3. Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant
4. Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
5. Gabapentin to treat itch in patients with liver disease
Related Studies:
Other Hepatitis C Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetics of Hepatitis C Virus Infection
|
|
|
|
|
|
|
|
